Current State of Clinical Care of People With Cystic Fibrosis
The advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has dramatically changed the landscape of the clinical care of people with cystic fibrosis (PwCF). In particular, highly effective modulator therapy (HEMT) availability for the majority of PwCF has led to changes in pharmacotherapy regimens and clinical outcomes but has also been associated with adverse effects and drug interactions. The role of CFTR modulator therapy perinatally continues to be of great interest, related to both the mother with CF as well as the infant in utero and after birth. As the median life expectancy for PwCF continues to increase, consideration must also be given for treatment of cardiovascular disease and other comorbidities as well as cancer screening and other preventative care measures.
Authors
- Wendy Bullington (ORCID: https://orcid.org/0000-0002-3336-1545)
- D. Young (ORCID: https://orcid.org/0000-0001-8630-3413)
- Jonathan J. Grant
- Paul M. Beringer (ORCID: https://orcid.org/0000-0002-3744-3310)
- Rebecca S. Pettit (ORCID: https://orcid.org/0000-0002-6049-0481)
- Brittany A. Wright (ORCID: https://orcid.org/0000-0001-6620-1727)
- Sabrina Nunes Garcia
- Charissa W. Kam
- Cameron J. McKinzie
Institutions
- University of Southern California (US)
- Johns Hopkins University (US)
- Medical University of South Carolina (US)
- University of Utah (US)
- Johns Hopkins Medicine (US)
- Riley Hospital for Children (US)
- St. Luke’s Boise Medical Center (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Montana (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2026-03-15
- DOI
- https://doi.org/10.1002/phar.70138
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00